Qualigen Therapeutics Strengthens Leadership With Key Executive And Board Appointments, Announces Auditor Change

Qualigen Therapeutics, Inc. has announced several key leadership and governance changes as part of its effort to strengthen the company’s executive team, improve financial oversight, and support the next phase of strategic growth. These changes reflect Qualigen’s focus on building a strong, globally oriented leadership structure with deep operational, financial, and industry expertise. Effective October 2, 2025, Jerry (Jiawei) Wang has been appointed as Co-Chief Executive Officer, and Koti Meka has joined as Chief Financial Officer. Both leaders bring extensive experience in corporate management and financial strategy, particularly from their previous roles at Faraday Future.

Mr. Wang, one of the original founding members and the Global President of Faraday Future, has played a vital role in shaping the company’s strategic direction since its establishment in 2014. He was instrumental in securing more than $3 billion in funding and led the successful initial public offering (IPO) of the company in 2021. His track record in global business development and capital management positions him well to drive Qualigen’s growth initiatives.

Mr. Meka, currently serving as the CFO of Faraday Future, also brings a strong background in corporate finance. Before joining Faraday Future in 2016, he spent 14 years at Ford Motor Company, where he worked across cost optimization, product development finance, and corporate finance. His appointment reinforces Qualigen’s commitment to enhancing financial transparency and operational efficiency.

Alongside these executive changes, Qualigen has expanded and restructured its Board of Directors following the completion of a private placement on September 29, 2025. Three new members have been appointed to the Board: Kevin Chen as Independent Director (appointed September 26, 2025), Chad Chen as Director, and Jay Sheng as Director. The company also announced new committee assignments. Jay Sheng will serve as Chairman of the Audit Committee, with Graydon Bensler and Chad Chen as members. In addition, Chad Chen, Kevin Chen, and Jay Sheng will serve on both the Nominating & Corporate Governance Committee and the Compensation Committee.

Each of the new board members brings valuable experience from diverse sectors. Mr. Sheng currently serves as a board member of Faraday Future and as Head of Operations & Finance Director of FF Global Partners LLC. Prior to that, he was Deputy Managing Director at China Aviation Fuel (Europe) Limited, a subsidiary of China Aviation Oil (Singapore) Corporation, which is listed on the Singapore Exchange and part of a Fortune 500 group.

Mr. Kevin Chen is the Chief Economist and Chief Investment Officer of Horizon Financial and serves on the boards of several publicly listed companies, including CurrenC Group, Australian Oilseeds Investments, Scage Future, and Capitan Investment Ltd. Beyond his corporate work, he contributes to academia as an adjunct associate professor at New York University and has served as a guest speaker at institutions such as Harvard University, Fordham University, Pace University, and IESE Business School.

Mr. Chad Chen, another Faraday Future board member, is a partner at Yoka | Smith, LLP, where he has practiced since 2012. His expertise covers litigation, business disputes, product liability defense, and class action cases, as well as non-litigation areas such as contract management, business transactions, and regulatory compliance. He has represented clients before several U.S. government agencies, including the Department of the Treasury and the Department of Commerce. Before joining Yoka Smith, he worked in-house at an alternative energy company.

In connection with these appointments, Cody Price and Robert Lim have resigned from Qualigen’s Board, while Campbell Becher has stepped down from his role as Director but will continue to serve as the Company’s President. The company clarified that all resignations were amicable and not related to any disagreement with its policies or operations.